Literature DB >> 16116931

Respiratory syncytial virus-related bronchiolitis in Puerto Rico.

María Molinari Such1, Inés García, Lourdes García, Gilberto Puig, Lourdes Pedraza, Jesús Marín, Marta Valcárcel.   

Abstract

BACKGROUND: Respiratory syncytial virus (RSV) is an important cause of respiratory tract disease in infants and young children. Immunoprophylaxis is available for high-risk infants. This study reviews infants with bronchiolitis at three primary care hospitals to describe the epidemiology of RSV infection in Puerto Rico.
METHODS: We analyzed data from 2 hospitals by obtaining the number of infants diagnosed with bronchiolitis and estimating the percentage of cases due to RSV. A third hospital included patients with confirmed RSV infection.
RESULTS: There were 4,557 patients in the study. RSV infection occurred throughout the year. Data shows a progressive decrease in RSV-positive infections.
CONCLUSIONS: Data confirms year-round incidence of RSV in Puerto Rico. A standardized surveillance system in Puerto Rico is imperative to determine RSV epidemiology. The decrease in positive RSV infections may be due to the introduction of immunoprophylaxis to high-risk patients.

Entities:  

Mesh:

Year:  2005        PMID: 16116931

Source DB:  PubMed          Journal:  P R Health Sci J        ISSN: 0738-0658            Impact factor:   0.705


  3 in total

1.  Viral Aetiology of Bronchiolitis in Hospitalised Children in a Tertiary Center in Tehran.

Authors:  Ali Akbar Rahbarimanesh; Anahita Izadi; Mahsa Ghajarzadeh
Journal:  Maedica (Bucur)       Date:  2018-03

2.  Epidemiology of bronchiolitis: a description of emergency department visits and hospitalizations in Puerto Rico, 2010-2014.

Authors:  Andrea Rivera-Sepulveda; Enid J Garcia-Rivera
Journal:  Trop Med Health       Date:  2017-10-02

3.  Risk Factors Associated With Bronchiolitis in Puerto Rican Children.

Authors:  Andrea Rivera-Sepúlveda; Enid García-Rivera; Mario Castro; Fernando Soto
Journal:  Pediatr Emerg Care       Date:  2021-12-01       Impact factor: 1.454

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.